Redeye was surprised by the strong profits again showing that Doro has reached a higher plateau in p...
Redeye leaves a comment on the Q4 report from Egetis Therapeutics released earlier this morning.
Stark tillväxt avslutar starkt 2021 Omsättningen för Q4 uppgick till 1 435 mkr (1079 mkr) mot våra e...
Ett fantastiskt år ramas in med en stark avslutning Rapporten för det fjärde kvartalet 2021 var geno...
Finnair’s Q4’21 losses were a bit lower than estimated, however the company expects the combination ...
NoHo Partners reported Q4 EBIT of EUR 6.7m, +58% (EUR 2.
Innofactor’s Q4 results were below our expectations.
Solteq’s Q4 was below our lowered pre-Q4 expectations, with revenue at EUR 18.
Raketech reported a solid Q4 overall, with revenues 4% below our expectations, whereas adjusted EBIT...
A particularly good shipping market was the main reason for Aspo's clear EBIT beat versus market con...
Redeye states that the Q4 report was weaker than expected and that customer projects will be delayed...
Redeye was surprised by QleanAir’s Q4 report in terms of growth but was left a bit disappointed on t...
Redeye is surprised to see another quarter of exceptional growth.
Redeye's preliminary revisions suggest a small increase in our sales forecast while leaving EBIT lar...
Redeye provides an initial take on Arise’s Q4 report, where both sales and EBITDA grew impressively ...
Redeye provides a comment on Gapwaves' year-end report.
Redeye's first impressions on the Q4 report from Bioservo earlier this morning.
Redeye shares its initial take on Stille’s Q4’21 report, which came in slightly below our expectatio...
Redeye will likely lower its fair value range after the sales miss in the year-end report.
Waystream reported their Q4 numbers earlier this morning.
